Full-Time

Senior Manager

Prior Authorization, Specialty Testing

Posted on 10/1/2025

Deadline 10/9/25
LabCorp

LabCorp

10,001+ employees

Global life sciences R&D services

Compensation Overview

$93k - $120k/yr

+ Bonus + Commission

Burlington, NC, USA

Remote

Position may require travel (up to 20%) to meet face-to-face with payers, industry leaders, and LabCorp business units.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis
Requirements
  • Five years direct relevant work experience with Bachelor’s degree OR nine years direct relevant work experience in lieu of degree required
  • Five plus years of successfully managing a team, either directly through leadership or indirectly through influence required
  • Strong understanding of genetics required
  • Familiarity with payer medical policies and laboratory billing at Labcorp required
  • Proven success in building and maintaining strategic relationships required
Responsibilities
  • Provide oversight of appeals for Specialty Testing
  • Provide strategic oversight of prior authorization processes for specialty testing, including evaluation of payer requirements, documentation standards, and opportunities to streamline workflows and improve approval rates
  • Develop strategy to optimize resources, people, and tools, including evaluation of which appeals should and should not be attempted in consideration of payer medical policies, cost of tests performed, patient medical records and potential reimbursement
  • Works directly with Specialty Testing Marketing Management teams to develop an understanding of existing and emerging technologies to provide education, appeals influence and insight pertaining to payer policy
  • Ability to clearly communicate with business units across Labcorp to assess need for appeals in specialty business segments
  • Ability to hold clinical discussions with payers or clients throughout the country regarding the information needed to support appeals
  • Manage informational needs of multiple cross-functional stakeholders regarding payer coverage and reimbursement policy issues and/or changes
  • (Team-only impact) Independently manage the day-to-day of team member questions regarding processes, time off, schedules, interpersonal relationships, etc.
  • (Company impact) With director oversight, include or exclude tests in the appeals process
  • (Company impact) With agreement from director, initiate payer outreach to overturn need for appeals on tests where payer is overturning denials a high percentage of the time
  • (Industry impact) Independently provide insight to associations, such as ACLA, about payer policy and payer edit issues
  • Obtain medically necessary documentation and information from Labcorp’s clients/offices
  • Explain complex appeals issues to RCM, Payor Solutions, and S&T leadership
  • Empower and motivate team members
  • Continually identify bottlenecks in the specialty testing appeals processes and help to resolve them through process redesign, resource assignment optimization, and automation opportunities
  • Translate complex appeals issues into easy-to-understand visuals and/or concise wording
  • Correlate payer medical policies, prior auth requirements, appeals requirements, Labcorp tests, and reimbursement
  • Work with Policy Reporter data to understand changes in payer policy impacting reimbursement
  • Collaborate with other departments/business associates to analyze, understand, and define business rules for Specialty Testing policy changes
  • Collaborate with Specialty Analytic/Support and Medical Policy teams to deploy best practices to support reimbursement capture
  • Exceptional writing skills in crafting effective appeals for specialty testing denials to include prior authorization efforts, supportive clinical evidence, complying with all clinical and billing policies, guidelines, and regulations
  • Conduct clinical evidence searches, utilize internal and external subject matter experts and/or other avenues of research to identify supportive evidence for coverage of Specialty Testing services
  • Maintain a thorough knowledge of regulatory processes and policy developments on matters affecting Labcorp Specialty testing. Communicate LabCorp’s policy positions, strategy and tactics, and advocate positions regarding new or amended legislation, regulations, or public policy
  • Support efforts at the state and federal levels as appropriate by developing responses, talking points, strategy on key issues while helping to assure policy consistency across the organization
  • Perform other and further duties and responsibilities as assigned
  • Position may require travel (up to 20%) to meet face-to-face with payers, industry leaders, and LabCorp business units
Desired Qualifications
  • Strong clinical experience with genetic or molecular testing
  • Able to communicate impactful industry changes in a concise and meaningful way to audiences of varying levels of understanding
  • Proven success in creating and maintaining a positive team culture with motivated employees, helping them to further develop and contribute even more to the company

Labcorp provides end-to-end R&D services for life sciences and agricultural clients, including crop protection, with testing and regulatory support. It runs physicochemical analyses, safety assessments, and inhalation toxicology studies using specialized labs to evaluate inhaled substances. It differentiates itself with a global footprint and an integrated set of services across the product lifecycle, including regulatory submissions. Its goal is to help clients bring safe, effective products to market efficiently by applying rigorous science and scalable testing.

Company Size

10,001+

Company Stage

IPO

Headquarters

Burlington, Vermont

Founded

1976

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $3.54B, up 5.8%, raising full-year guidance to $14.73B.
  • AI Alzheimer's platform validates spring 2026, expands to oncology and cardiometabolic areas.
  • Optum.ai partnership automates lab workflows and enhances patient engagement.

What critics are saying

  • Quest Diagnostics outgrows Labcorp at 9.2% versus 5.8%, eroding diagnostics share in 6-12 months.
  • NeoGenomics seizes oncology volume with 11.1% growth, hitting Labcorp's specialty testing now.
  • Tempus commoditizes Labcorp's AI platform with superior EHR integration in 24 months.

What makes LabCorp unique

  • Labcorp's AI platform with AWS and Datavant analyzes Alzheimer's data in minutes using deidentified lab datasets.
  • Labcorp holds first FDA clearance for rapid fentanyl urine test in emergency settings.
  • Labcorp's Plasma Detect Genome MRD assesses NSCLC recurrence risk via whole-genome sequencing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Tuition Reimbursement

Employee Stock Purchase Plan

Company News

360Dx
May 5th, 2026
Fox Chase Cancer Center, Labcorp collaborate on clinical trial for Plasma Detect Genome MRD in NSCLC.

Fox Chase Cancer Center, Labcorp collaborate on clinical trial for Plasma Detect Genome MRD in NSCLC. NEW YORK - Temple Health's Fox Chase Cancer Center and Laboratory Corporation of America announced Tuesday a clinical trial collaboration to evaluate the use of Labcorp's whole-genome sequencing Plasma Detect Genome MRD to assess the risk of recurrence in patients with early stage non-small cell lung cancer (NSCLC). Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Resonate Group
Apr 15th, 2026
Labcorp launches rapid fentanyl test with 48-hour detection window.

Labcorp launches rapid fentanyl test with 48-hour detection window. * April 15, 2026 While fentanyl overdose deaths have been falling in recent years, use of the drug remains a major public health crisis in the U.S., and now Labcorp is launching a new test designed to detect the drug's use for up to 48 hours after exposure. Fields (*) Mark are Required

PR Newswire
Apr 14th, 2026
Labcorp launches AI-powered platform with AWS and Datavant to accelerate Alzheimer's research

Labcorp has launched an AI-powered real-world data platform to accelerate Alzheimer's disease research, developed in collaboration with Amazon Web Services and Datavant. The platform aims to generate insights in minutes that previously required months of data analysis. The system combines Labcorp's diagnostic and genomic datasets with medical claims data, using AWS AI services including Amazon Bedrock and Amazon SageMaker. It enables researchers to identify patient cohorts, track disease progression and measure treatment effectiveness across diverse populations using deidentified healthcare data. With over 7.2 million Americans living with Alzheimer's and annual care costs exceeding $380 billion in the US, the platform addresses traditional challenges of fragmented data and lengthy preparation times. Initial validation will complete in spring 2026, with plans to expand into inflammatory diseases, cardiometabolic conditions, women's health and oncology.

360Dx
Apr 13th, 2026
Labcorp, CHOP to develop, commercialize specialty pediatric diagnostics.

Labcorp, CHOP to develop, commercialize specialty pediatric diagnostics. NEW YORK - Laboratory Corporation of America and Children's Hospital of Philadelphia (CHOP) on Monday announced a strategic collaboration to accelerate the development of and access to specialized pediatric diagnostics. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

360Dx
Mar 20th, 2026
In brief this week: Labcorp, guardant Health, waters, fulgent genetics, more.

In brief this week: Labcorp, guardant Health, waters, fulgent genetics, more. NEW YORK - Laboratory Corporation of America this week said it has completed its acquisition of select assets of Crouse Health's Laboratory Alliance of Central New York's laboratory business. The two firms also have entered into a deal for Crouse Health to manage the daily operations of its inpatient lab, while Labcorp will take over operations of the lab alliance's 12 patient service centers. It said in a statement that the deal will improve access to high-quality, affordable diagnostic services in Central New York by offering patients and providers Labcorp's expanded testing menu, data, and digital tools. To read the full story... What's Popular?

INACTIVE